Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
MA

NASDAQ · MAIA

MAIA Biotechnology, Inc.

Healthcare · Biotechnology

$1.22

Up+$0.07 (+6.09%)

Updated Oct 12, 2026, 5:58 AM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
60.55M
P/E ratio
-3.06
Dividend yield
0.00%
52-week range
$0.87 – $3.19
Volume
375.3K
Avg. volume
630.4K

Price performance · MAIA

MAIA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

MAIA closed at $1.22 after 20 trading sessions, down 12.23% for the selected period.

Last close
$1.22
Period change
-12.23%
Period low
$1.15
Period high
$1.40
Daily close
View OHLC price history
MAIA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$1.16$1.24$1.16$1.22375.3K
Oct 8, 2026$1.15$1.16$1.13$1.15677.14K
Oct 7, 2026$1.17$1.22$1.16$1.18359.68K
Oct 6, 2026$1.20$1.21$1.175$1.19227.16K
Oct 5, 2026$1.17$1.21$1.17$1.18531.01K
Oct 2, 2026$1.19$1.21$1.17$1.19405.03K
Oct 1, 2026$1.18$1.22$1.15$1.17781.51K
Sep 30, 2026$1.17$1.19$1.15$1.18691.46K
Sep 29, 2026$1.20$1.215$1.15$1.15677.55K
Sep 28, 2026$1.23$1.2645$1.18$1.181.01M
Sep 25, 2026$1.27$1.33$1.20$1.20920.68K
Sep 24, 2026$1.31$1.33$1.25$1.25595K
Sep 23, 2026$1.35$1.36$1.30$1.32627.03K
Sep 22, 2026$1.33$1.37$1.31$1.37940.37K
Sep 21, 2026$1.35$1.38$1.30$1.331.14M
Sep 18, 2026$1.37$1.3977$1.31$1.31468.26K
Sep 17, 2026$1.44$1.45$1.36$1.40649.2K
Sep 16, 2026$1.35$1.42$1.34$1.40907.38K
Sep 15, 2026$1.42$1.46$1.33$1.341.19M
Sep 14, 2026$1.30$1.40$1.30$1.39800.15K

Latest MAIA news

The latest Smart Investors Daily articles mentioning MAIA.

Stock researchCompany · Overview

MAIA research

Overview

Company profile and research snapshot.

Company profile

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.38
Implied upside
—
Analysts
7
MAIA recent ratings
DateFirmRatingTarget
Feb 21, 2023Noble Capital MarketsOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an enrollment milestone with 150 patients treated with ateganosine sequenced with an immune checkpoint inhibitor (CPI

Yahoo · Sep 23, 2026

MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal

THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National Authority of Medicines and Health Products (INFARMED) to begin screening patients for

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By